Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol in active non-radiographic axial spondyloarthritis
2015-001894-41Phase 3Completed
- Sponsor
- UCB
- Start
- Aug 2015
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-radiographic axial spondyloarthritis (nr-axSpA) comparing Certolizumab pegol with Placebo (2 arms). Primary endpoint: Ankylosing Spondylitis Disease Activity Score major improvement response at Week 52. Started Aug 2015; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
non-radiographic axial spondyloarthritis (nr-axSpA)
Beyond the preview
Go deeper on 2015-001894-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001894-41.